Novartis announced today that Cosentyx® (secukinumab) met the primary endpoints in two new clinical studies, showing superior efficacy compared to

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

New User Registration
Please indicate that you agree to the Terms of Service *
*Required field